Brian Rifkin

June 25, 2025

tweetorial

Is tacrolimus superior to MMF in pediatric steroid sensitive nephrotic syndrome?

Brian Rifkin

June 25, 2025

tweetorial

Is tacrolimus superior to MMF in pediatric steroid sensitive nephrotic syndrome?

MMF versus TAC in pediatric SSNS with FRNS and SDNS

Guest User

January 21, 2023

tweetorial

IgA and steroids: the saga continues

Guest User

January 21, 2023

tweetorial

Drug reps pitching you Nefecon? Catch-up with the RCT in our #TenTweetNephJC tweetorial

#TenTweetNephJC returns in 2023! Catch-up rapidly with the biggest trials in nephrology.

Up first is NefIgArd.

We all say we hate steroids, but really we love their efficacy but hate their side-effects, right?

IgA nephropathy is again the subject of a steroid trial🧵 pic.twitter.com/sh0xtKPhsP
— Nephrology Journal Club (@NephJC) January 20, 2023

Guest User

June 5, 2022

Background

Re-TESTING Steroids for IgA Nephropathy

Guest User

June 5, 2022

Background

Coming up next we have the TESTING RCT (again), with updated results on methylprednisolone treatment for IgA nephropathy.

swapnil hiremath

January 25, 2022

Background

Scheduling Steroids to Remedy Relapses

swapnil hiremath

January 25, 2022

Background

This week, we will discuss two trials with a joint IPNA JC session. PREDNOS 2 explores and explodes the steroids use in URTI to prevent relapse practice, while another noninferiority trial reports use of lower dose steroids in managing relapses.

joel topf

June 25, 2019

Background

How Long is too Long? Steroids in Nephrotic Syndrome

joel topf

June 25, 2019

Background

How Long is too Long? Steroids in Nephrotic Syndrome

This week, we will discuss an RCT, a pediatric RCT, and a pediatric RCT in childhood nephrotic syndrome! A trial that asks a question of burning importance to the management of childhood nephrotic syndrome. Join us as we tackle PREDNOS.

swapnil hiremath

August 28, 2017

Background

IgA Nephropathy: Testing Steroids Again

swapnil hiremath

August 28, 2017

Background

Stop-IgAN suggested steroids may not be useful in patients with intermediate range proteinuria. Now, in a different population with more proteinuria, TESTING finds a mixed result: some benfit + more adverse events. Should we keep on TESTING?